Wake Forest Baptist COVID study finds higher positive antibodies rate

Wake Forest Baptist COVID study finds higher positive antibodies rate

Only $3 for 13 weeks
LabCorp (copy)

Fingerstick for COVID-19 antibody test.

The latest update on Wake Forest Baptist Medical Center’s testing for COVID-19 antibodies has found an increase in positive test rates among North Carolinians.

The positive test rate was 3% on June 8, but increased to between 8% and 10% as of June 15.

A positive test signifies that an individual has been infected with the virus, whether symptomatic or asymptomatic.

Antibodies generally can be detected in a person’s blood 14 days after the start of symptoms, which means the data collected through this study will be a lagging indicator of the virus’s prevalence in the population.

Antibodies are measured by medical researchers to determine levels of community spread with viruses. They are typically disease specific.

Wake Forest Baptist began testing in April with Atrium Health also participating. Eligible  patients are those who have received care within their health systems. The bulk of the participants to date are between ages 50 and 75, but ranges from 16 to 95.

As of June 15, there were 17,825 participants enrolled in the Community Partnership Research study, primarily in Davidson, Forsyth, Guilford and Randolph counties. There have been 442,759 completed daily symptom logs.

At an 8% positive rate, that means 1,426 study participants have shown to have the antibodies. At 10%, there have been 1,782 participants.

Many of the positive antibody tests have been found in south Winston-Salem and southwest Forsyth, and western Greensboro and High Point. The positive tests for the virus appear to be concentrated in south Winston-Salem and southwest Forsyth.





Concerned about COVID-19?

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.